You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Dow
Baxter
Colorcon
AstraZeneca

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,527,833

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,527,833 protect, and when does it expire?

Patent 9,527,833 protects LONSURF and is included in one NDA.

This patent has thirty-five patent family members in eighteen countries.

Summary for Patent: 9,527,833
Title:Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Abstract: An objective of the present invention is to obtain a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride. The present invention provides a crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting characteristic peaks at angles of 11.6.degree., 17.2.degree., 17.8.degree., 23.3.degree., 27.1.degree., and 29.3.degree. as a diffraction angle (2.theta..+-.0.1.degree.) in powder X-ray diffraction.
Inventor(s): Kazuno; Hideki (Ibaraki, JP), Mutsumi; Tomonobu (Saitama, JP)
Assignee: TAIHO PHARMACEUTICAL CO., LTD. (Tokyo, JP)
Application Number:14/896,748
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Formulation;

Drugs Protected by US Patent 9,527,833

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Taiho Oncology LONSURF tipiracil hydrochloride; trifluridine TABLET;ORAL 207981-001 Sep 22, 2015 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Taiho Oncology LONSURF tipiracil hydrochloride; trifluridine TABLET;ORAL 207981-002 Sep 22, 2015 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,527,833

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2013-126567Jun 17, 2013
PCT Information
PCT FiledJune 17, 2014PCT Application Number:PCT/JP2014/065985
PCT Publication Date:December 24, 2014PCT Publication Number: WO2014/203877

International Family Members for US Patent 9,527,833

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014282281   Start Trial
Australia 2017208215   Start Trial
Australia 2018219967   Start Trial
Brazil 112015031619   Start Trial
Canada 2914999   Start Trial
Canada 2985006   Start Trial
China 104395307   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Colorcon
Merck
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.